- Home
- KZIA vs QTRX Comparison
KZIA vs QTRX Comparison
Compare KZIA & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | QTRX |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 160.0M |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KZIA | QTRX |
|---|---|---|
| Price | $8.06 | $2.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $28.33 | $3.17 |
| AVG Volume (30 Days) | 248.3K | ★ 500.8K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | N/A | $3.21 |
| Revenue Next Year | N/A | $9.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $4.86 | $2.15 |
| 52 Week High | $17.40 | $8.77 |
Technical Indicators
Market Signals| Indicator | KZIA | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 41.78 |
| Support Level | $6.72 | $2.34 |
| Resistance Level | $8.18 | $3.99 |
| Average True Range (ATR) | 0.67 | 0.23 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 48.51 | 12.64 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.